Cardiovascular Complication Articles & Analysis
13 news found
“Patients with chronic kidney disease are faced with an increased risk of cardiovascular events,” said Professor Peter Rossing, Head of Complications Research at the Steno Diabetes Center Copenhagen. “As chronic kidney disease progresses silently, with oftentimes no symptoms in the early stages, patients with type 2 diabetes should be regularly ...
ByBayer AG
The positive data from FIGARO-DKD demonstrated that finerenone significantly reduced the risk of cardiovascular events in adult patients with CKD and T2D. “As patients are faced with an increased risk of cardiovascular events already in early stages of chronic kidney disease and type 2 diabetes, and as this risk is growing with kidney health decline, ...
ByBayer AG
“Patients need to be screened regularly and treated early to prevent them from progressing to more advanced stages of chronic kidney disease, as this may lead to better outcomes for these patients, potentially preventing cardiovascular complications and death,” said Dr. Michael Devoy, Chief Medical Officer of Bayer AG's Pharmaceutical Division. ...
ByBayer AG
Dialysis treatment can reduce life expectancy by two thirds and almost half of patients die from cardiovascular complications, in part caused by the immune system reacting to components of the dialysis apparatus. ...
This suppresses the blood’s foreign body response preventing a repetitive, hostile inflammatory reaction that increases the risk of cardiovascular and other complications. Peritoneal Dialysis (PD) offers considerable benefits to patients but it has a high dropout rate, which has limited its adoption compared to Haemodialysis. ...
The simulation is intended to boost physician confidence, reduce operating times, and decrease the risk of complications. Cardiovascular transcatheter therapies have transformed the treatment landscape, expanding options for patients with structural heart disease. ...
ByBIOMODEX
This suppresses the blood’s foreign body response, thereby preventing a repetitive, hostile inflammatory reaction that increases the risk of cardiovascular complications. The technology may also be used with other devices or treatments such as CRRT, ECMO, cardiopulmonary bypass, organ transplants and immunomodulating therapeutics. ...
Bicuspid aortic valve (BAV) is the most common congenital heart defect, affecting up to 2% of the population, and carries a significant risk of cardiovascular complications. Approximately 53% of BAV patients require aortic valve surgery within 25 years of being diagnosed.[1] Most BAV patients undergo aortic valve replacement between 40 and 60 years of age, ...
Solvay Ventures announces today its equity investment in Invizius, the University of Edinburgh spin-out developing potentially lifesaving products that reduce complications rates suffered by dialysis patients. Solvay Ventures invests alongside Mercia Asset Management, Downing Ventures, the University of Edinburgh’s Old College Capital fund and the Scottish Investment Bank. ...
Invizius’s technology stems from research by the company’s co-founder and CTO, Dr Andy Herbert, and his team who believe it could reduce the huge death toll from cardiovascular disease among long-term dialysis patients. Currently life expectancy on dialysis is just one-third of normal, and half of patients die from cardiovascular ...
It can also put patients at a higher risk for cardiovascular complications, and death. CLI is considered the “end stage” of peripheral arterial disease (PAD). ...
Despite improvements in dialysis therapy, cardiovascular disease remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications, and life expectancy on dialysis is just one-third of that for the general population. ...
Scientists conclude that future research on the alteration of microbiota in T2D patients, or in other frequent chronic diseases, such as cardiovascular or neurological complications, must consider the effects of drug ...